Technical Analysis for SCLP - Scancell Holdings Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | -1.49% | |
| Stochastic Reached Overbought | Strength | -1.49% | |
| Wide Bands | Range Expansion | -1.49% | |
| Overbought Stochastic | Strength | -1.49% | |
| Calm After Storm | Range Contraction | -2.22% | |
| NR7 | Range Contraction | -2.22% | |
| Narrow Range Bar | Range Contraction | -2.22% | |
| Inside Day | Range Contraction | -2.22% | |
| Wide Bands | Range Expansion | -2.22% | |
| Crossed Above 200 DMA | Bullish | -2.22% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 6 minutes ago |
| Down 1% | 6 minutes ago |
| Up 1% | 6 minutes ago |
| Possible NR7 | about 20 hours ago |
| Up 1% | 1 day ago |
Free Daily (Stock) Chart Reading
Scancell Holdings Plc Description
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Medicine Pipe Cancer Branches Of Biology Clinic Medical Specialties Biopharmaceutical Therapy Clinical Trial Immunology Tumor Antibodies Immune System Monoclonal Antibodies Antibody Therapies Vaccine Lung Cancer Treatment Of Cancer Immunotherapies Cancer Therapeutics Immunotherapy Monoclonal Antibody
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.4 |
| 52 Week Low | 7.588 |
| Average Volume | 908,249 |
| 200-Day Moving Average | 16.13 |
| 50-Day Moving Average | 11.31 |
| 20-Day Moving Average | 12.45 |
| 10-Day Moving Average | 15.49 |
| Average True Range | 1.10 |
| RSI (14) | 71.75 |
| ADX | 35.34 |
| +DI | 43.13 |
| -DI | 15.02 |
| Chandelier Exit (Long, 3 ATRs) | 14.99 |
| Chandelier Exit (Short, 3 ATRs) | 10.90 |
| Upper Bollinger Bands | 19.26 |
| Lower Bollinger Band | 5.63 |
| Percent B (%b) | 0.82 |
| BandWidth | 109.54 |
| MACD Line | 1.76 |
| MACD Signal Line | 1.18 |
| MACD Histogram | 0.5812 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.39 | ||||
| Resistance 3 (R3) | 17.42 | 17.23 | 17.28 | ||
| Resistance 2 (R2) | 17.23 | 17.07 | 17.22 | 17.25 | |
| Resistance 1 (R1) | 16.99 | 16.97 | 16.90 | 16.96 | 17.21 |
| Pivot Point | 16.81 | 16.81 | 16.76 | 16.79 | 16.81 |
| Support 1 (S1) | 16.57 | 16.65 | 16.48 | 16.54 | 16.29 |
| Support 2 (S2) | 16.38 | 16.55 | 16.37 | 16.25 | |
| Support 3 (S3) | 16.14 | 16.38 | 16.22 | ||
| Support 4 (S4) | 16.11 |
